OncoMatch/Clinical Trials/NCT06479356
CD19-targeted CAR T Cells for Relapsed or Refractory (R/R) Large B-cell Lymphoma
Is NCT06479356 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Relma-cel for non-hodgkin lymphoma.
Treatment: Relma-cel — This is an open-label, single-arm study to treat the adult R/R Large B-cell Lymphoma subjects with Relmacabtagene autoleucel (relma-cel) in China.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Diffuse Large B-Cell Lymphoma
Biomarker criteria
Required: CD19 expression (positive)
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: anthracycline
treated with anthracyclines and rituximab(or other CD20-targeted antibodies) and had relapsed, failed to respond, or progressed after at least two lines of therapy including autologous hematopoietic stem cell transplantation(auto-HSCT)
Must have received: CD20-targeted therapy (rituximab)
treated with anthracyclines and rituximab(or other CD20-targeted antibodies) and had relapsed, failed to respond, or progressed after at least two lines of therapy including autologous hematopoietic stem cell transplantation(auto-HSCT)
Must have received: autologous hematopoietic stem cell transplant
at least two lines of therapy including autologous hematopoietic stem cell transplantation(auto-HSCT)
Cannot have received: CAR T-cell therapy
Received CAR T-cell or other genetically-modified T-cell therapy previously
Lab requirements
Blood counts
Adequate organ function
Kidney function
Adequate organ function
Liver function
Adequate organ function
Adequate organ function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify